Ken Griffin Aurinia Pharmaceuticals Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$5.32 - $7.33 $163,324 - $225,031	30,700 Added 27.71%	141,500 $1.04 Million
Q2 2024 Aug 14, 2024	SELL	$4.81 - $5.78 $116,882 - $140,454	-24,300 Reduced 17.99%	110,800 $632,000
Q1 2024 May 15, 2024	SELL	$4.93 - $9.31 $2.36 Million - $4.46 Million	-478,800 Reduced 77.99%	135,100 $676,000
Q4 2023 Feb 14, 2024	BUY	$7.13 - $9.49 $712,287 - $948,051	99,900 Added 19.44%	613,900 $5.52 Million
Q3 2023 Nov 14, 2023	BUY	$7.77 - $12.27 $568,764 - $898,164	73,200 Added 16.61%	514,000 $3.99 Million
Q2 2023 Aug 14, 2023	SELL	$8.96 - $11.69 $3.02 Million - $3.93 Million	-336,500 Reduced 43.29%	440,800 $4.27 Million
Q1 2023 May 15, 2023	BUY	$5.94 - $11.27 $229,878 - $436,149	38,700 Added 5.24%	777,300 $8.52 Million
Q4 2022 Feb 14, 2023	SELL	$4.11 - $8.14 $251,121 - $497,354	-61,100 Reduced 7.64%	738,600 $3.19 Million
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $962,370 - $1.79 Million	-144,500 Reduced 15.3%	799,700 $6.01 Million

208

58.6M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.26B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.